Shattuck Labs Inc
STTK
ISIN null / Valor 57260669
Shattuck Labs Inc
UMushroom community rating:
About company
Shattuck Labs Inc. is a biotechnology firm focused on the development of innovative immunotherapy treatments. The company has built a significant portfolio, comprising over 400 bi-functional fusion proteins. These proteins are designed to target a range of clinically validated and emerging pathways, enabling Shattuck Labs to develop therapies that aim to be both best-in-class and first-in-class. This approach suggests a strategic focus on leveraging cutting-edge science to address unmet medical needs in the field of immunotherapy, positioning the company at the forefront of advancements in treatment methodologies. Through its proprietary technologies and extensive portfolio, Shattuck Labs seeks to make a meaningful impact on patient care in the oncology and autoimmune disease spaces.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (10.11.2025):
Shattuck Labs Inc reported its financial results for the third quarter of 2025, demonstrating improved cost management and a robust cash position despite ongoing investment in its clinical pipeline. The company’s Q3 2025 results highlight a reduced net loss, lower R&D and G&A expenses compared to last year, and a strong capital base supported by a recently closed $103 million private placement—all set against continued progress with its lead candidate SL-325.
Improved Net Loss
In Q3 2025, Shattuck Labs Inc registered a net loss of $10.1 million (or $0.14 per share) compared to $16.6 million (or $0.33 per share) in Q3 2024, reflecting better cost control and operational efficiencies.
Lower R&D and G&A Expenses
Research and Development expenses fell to $7.6 million from $16.3 million, and General and Administrative expenses decreased from $4.6 million to $4.1 million, demonstrating a focused approach on resource allocation during Q3 2025.
Strengthened Cash Position
Shattuck Labs Inc reported cash, cash equivalents, and short-term investments of $86.1 million as of September 30, 2025. Coupled with the $103 million private placement closed in August 2025, the company is well-equipped to fund its operations through 2029.
Advancing Clinical and Pipeline Programs
The Q3 2025 period also marked a significant milestone for the SL-325 program, with the dosing of the first participants in its Phase 1 clinical trial. This progress supports Shattuck Labs Inc’s strategic plans to advance SL-325 into Phase 2 trials and enhance its broader pipeline development.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
97 M
Market cap (USD)
93,706
Daily traded volume (Shares)
1.3 / 1.17
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
